Alpha Tau Medical Ltd. DRTS
13.72 USD +0.42 (+3.16%)
At closeNov 6, 2026, 6:52 PM EST
13.98 +0.26 +1.92%
After hours · Nov 6, 6:52 PM ET
13.16 Day range 13.97
3.43 52-week range 15.79
- YTD
- +177.17%
- 1 year
- +261.05%
- Market cap
- 1.27B
- EPS (ttm)
- -1.04
- Shares out
- 92.48M
- Forward P/E
- -25.67
- YTD return
- +177.17%
- 1-year return
- +261.05%
- Volume
- 417.32K
- Avg volume
- 542.28K
- Open
- 13.51
- Previous close
- 13.30
- Day's range
- 13.16 – 13.97
- 52-week range
- 3.43 – 15.79
- Beta
- 1.29
- Analysts
- Buy
- Price target
- 17.80 (+29.7%)
- Earnings date
- Nov 19, 2026
ALL +3.51 (+35.85%)
Key statistics
- Enterprise value
- 1.14B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 28.76
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -20.26M
- Total cash
- 100.64M
- Total debt
- 15.15M
- Return on equity
- -141.68%
- Short % of float
- 5.35%
- 50-day average
- 14.15
- 200-day average
- 10.73
Analyst view
Consensus: buy
Buy
Price target (mean) 17.80 +29.7% upside
Now 13.72
- Target (low)
- 8.00
- Target (mean)
- 17.80
- Target (high)
- 30.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 19, 2026
Expected Nov 19, 2026. Consensus EPS estimate -0.14672.
Financials — quick view
DRTS Revenue — quarterly 0
DRTS Net income — quarterly -45.81M
DRTS EPS — quarterly -0.50
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2026 | Sep 30, 2026 | -0.14 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.14088 | -0.50 | -0.36 | -254.91% |
| May 18, 2026 | Mar 31, 2026 | -0.13 | -0.26 | -0.13 | -100.00% |
| Mar 9, 2026 | Dec 31, 2025 | -0.13 | -0.14 | -0.01 | -7.69% |
| Nov 20, 2025 | Sep 30, 2025 | -0.12 | -0.14 | -0.02 | -16.67% |
| Aug 11, 2025 | Jun 30, 2025 | -0.12 | -0.13 | -0.01 | -8.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 3, 2026 | Barclays | main | Overweight | Overweight |
| Aug 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 22, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 16, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- alphatau.com
News
Alpha Tau Medical To Join TASE’s TA-90 and TA-125 Indices On November 5, 2026 
Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients 
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target 
Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study - Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30
HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16 - Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate
- HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target
- Alpha Tau Medical Announces Positive Data In Head And Neck Cancer Treatment Study, Hitting 100% Objective Response Rate Across Nine Evaluable Patients
12 Health Care Stocks Moving In Friday's Intraday Session
Your note
Sign in to keep a note on DRTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LEVY RAPHI | Chief Financial Officer | Sale | Aug 20, 2026 | 90,180 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gem Investment Advisors, LLC | 2.07% | 1,434,476 | 19.68M | Jun 29, 2026 |
| HighTower Advisors, LLC | 1.26% | 874,994 | 12.00M | Jun 29, 2026 |
| Boothbay Fund Management, LLC | 1.12% | 773,481 | 10.61M | Jun 29, 2026 |
| Aquamarine Financial (cayman) Ltd | 1.04% | 721,501 | 9.90M | Jun 29, 2026 |
| Pier Capital, LLC | 1.00% | 691,939 | 9.49M | Jun 29, 2026 |
| UBS Group AG | 0.93% | 642,263 | 8.81M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core MSCI EAFE ETF | 0.68% | 470,946 | 6.46M | Sep 29, 2026 |
| iShares Trust-iShares MSCI EAFE Small-Cap ETF | 0.31% | 217,272 | 2.98M | Sep 29, 2026 |
| ARK ETF Trust-ARK Israel Innovative Technology ETF | 0.27% | 184,377 | 2.53M | Sep 29, 2026 |
| RBB Fund, Inc.-Adara Smaller Companies Fund | 0.19% | 134,468 | 1.84M | Sep 29, 2026 |
| iShares, Inc.-iShares MSCI Israel ETF | 0.19% | 133,302 | 1.83M | Sep 29, 2026 |
| Dunham Funds-Dunham Small Cap Growth Fund | 0.10% | 71,660 | 983.17K | Jul 30, 2026 |